WasabiCard serves over 500 corporate clients, accelerating the global expansion of its stablecoin payment ecosystem.
According to ChainCatcher, WasabiCard has announced that its number of corporate clients has officially surpassed 500, further accelerating the company’s global stablecoin payment infrastructure deployment. As a global payments infrastructure platform based on stablecoins, WasabiCard focuses on two core product ecosystems: global card issuance and global remittance, continuously providing enterprises and users worldwide with services such as card issuance, payments, subscriptions, remittances, payroll, and cross-border fund distribution.
In the past year, WasabiCard has issued over 500,000 cards, with its business covering more than 30 countries and regions. The cumulative transaction volume has exceeded $1 billion, and service scenarios include AI & SaaS subscriptions, advertising spend, cross-border payroll, Web3 payments, and global fund settlement across multiple sectors.
WasabiCard stated that as stablecoins are gradually entering real commercial scenarios, enterprises’ demand for more efficient, flexible, and programmable global payment infrastructure continues to grow. The company will further increase efforts in stablecoin payments, global fund flows, and the construction of programmable financial infrastructure in the future.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Analyst Gu Jingci: Follow the trend and adapt flexibly
XRP Ledger adds account control feature, enabling enterprises to manage assets offline.
BUZZ - Goldman Sachs says the price cap on cancer drugs has limited impact on Indian hospitals
October 9 – Goldman Sachs pointed out that India's implementation of a 30% profit margin cap on non-scheduled anticancer drugs (link) will have limited impact on hospitals. The report states that, based on preliminary discussions with hospital chain groups, such drugs account for less than 5% of hospital revenue and 2% to 2.5% of operating profit. The report adds that hospitals can offset the losses by slightly adjusting service charges, such as administration fees. According to a government notice, an expert committee will finalize the list of drugs to be brought under regulation. Driven by the anticipated price cap, the share prices of Max Healthcare MAXE.NS, Apollo Hospitals APLH.NS, and Fortis Healthcare FOHE.NS rose by 1.6% to 2.5%. Previously, since September 30, these stocks had collectively declined by 11% to 11.5%. Year-to-date, FOHE and MAXE are down 11.7% and 14.8%, respectively, while APLH has risen by 11%. (To assist non-English speakers, Reuters provides automated translations of its reports into several other languages. Due to potential errors or missing context in automated translations, Reuters does not guarantee the accuracy of automatic translation texts and offers them solely for readers’ convenience. Reuters accepts no responsibility for any damage or loss caused by using these automated translation features.)
Adding insult to injury! Japanese electronics giant Nidec downgraded by UBS, stock price plunges over 9% and approaches an 11-month low
UBS has downgraded Nidec's rating from "Buy" to "Neutral" and lowered its target price from 2,800 yen to 2,400 yen, citing a more challenging market environment.
Crypto prices
More
